172 related articles for article (PubMed ID: 36589225)
1. CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study.
Huang X; Liu W; Liu C; Hu J; Wang B; Ren A; Huang X; Yuan Y; Liu J; Li M
Front Mol Biosci; 2022; 9():983410. PubMed ID: 36589225
[No Abstract] [Full Text] [Related]
2. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
[TBL] [Abstract][Full Text] [Related]
3. OSCC cell-secreted exosomal CMTM6 induced M2-like macrophages polarization via ERK1/2 signaling pathway.
Pang X; Wang SS; Zhang M; Jiang J; Fan HY; Wu JS; Wang HF; Liang XH; Tang YL
Cancer Immunol Immunother; 2021 Apr; 70(4):1015-1029. PubMed ID: 33104837
[TBL] [Abstract][Full Text] [Related]
4. CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH; Wang CH; Chen HM; Zhang RX; Pan ZZ; Lu ZH; Wang GY; Yue X; Huang W; Liu RY
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579737
[TBL] [Abstract][Full Text] [Related]
5. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer.
Lu ZM; Pan SL; Yuan WL; Feng JL; Tian D; Shang XQ
Medicine (Baltimore); 2023 Dec; 102(50):e36480. PubMed ID: 38115316
[TBL] [Abstract][Full Text] [Related]
6. CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.
Chen X; Shen H; Liu H; Tan L; Zhang N
Funct Integr Genomics; 2024 Jan; 24(1):10. PubMed ID: 38221563
[TBL] [Abstract][Full Text] [Related]
7. CMTM6 promotes migration, invasion, and EMT by interacting with and stabilizing vimentin in hepatocellular carcinoma cells.
Huang X; Xiang L; Wang B; Hu J; Liu C; Ren A; Du K; Ye G; Liang Y; Tang Y; Yang D; Yuan Y
J Transl Med; 2021 Mar; 19(1):120. PubMed ID: 33757532
[TBL] [Abstract][Full Text] [Related]
8. Chemokine-like factor-like MARVEL transmembrane domain containing 6: Bioinformatics and experiments
Meng H; Li S; Li Q; Wang Y; Wang G; Qu Y
Front Mol Neurosci; 2022; 15():1026927. PubMed ID: 36698778
[TBL] [Abstract][Full Text] [Related]
9. The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer.
Tian Y; Sun X; Cheng G; Ji E; Yang S; Feng J; Zheng L
Ann Transl Med; 2021 Jan; 9(2):131. PubMed ID: 33569433
[TBL] [Abstract][Full Text] [Related]
10. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
11. Increased CMTM6 can predict the clinical response to PD-1 inhibitors in non-small cell lung cancer patients.
Koh YW; Han JH; Haam S; Jung J; Lee HW
Oncoimmunology; 2019; 8(10):e1629261. PubMed ID: 31646074
[TBL] [Abstract][Full Text] [Related]
12. CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway.
Liang HY; Chen SL; Cai SH; Zhang SW; Yang X; Wei LJ; Luo RZ; Liu LL
J Med Virol; 2023 Mar; 95(3):e28605. PubMed ID: 36815510
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment.
Zhao Y; Zhang M; Pu H; Guo S; Zhang S; Wang Y
Front Oncol; 2020; 10():585961. PubMed ID: 33552963
[TBL] [Abstract][Full Text] [Related]
14. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
Zhang C; Zhao S; Wang X
Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
[TBL] [Abstract][Full Text] [Related]
15. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
[TBL] [Abstract][Full Text] [Related]
16. CMTM6, a potential immunotherapy target.
Liang J; Li S; Li W; Rao W; Xu S; Meng H; Zhu F; Zhai D; Cui M; Xu D; Cai J; Zhang B
J Cancer Res Clin Oncol; 2022 Jan; 148(1):47-56. PubMed ID: 34783871
[TBL] [Abstract][Full Text] [Related]
17. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers.
Gao F; Chen J; Wang J; Li P; Wu S; Wang J; Ji Y
Biochem Biophys Rep; 2019 Dec; 20():100690. PubMed ID: 31646201
[TBL] [Abstract][Full Text] [Related]
18. Quantitative Assessment of CMTM6 in the Tumor Microenvironment and Association with Response to PD-1 Pathway Blockade in Advanced-Stage Non-Small Cell Lung Cancer.
Zugazagoitia J; Liu Y; Toki M; McGuire J; Ahmed FS; Henick BS; Gupta R; Gettinger SN; Herbst RS; Schalper KA; Rimm DL
J Thorac Oncol; 2019 Dec; 14(12):2084-2096. PubMed ID: 31605795
[TBL] [Abstract][Full Text] [Related]
19. Impact of CKLF-like MARVEL transmembrane domain containing 6 (CMTM6) expression in gastric cancer.
Nishi M; Shimada M; Yoshikawa K; Higashijima J; Tokunaga T; Kashihara H; Takasu C; Eto S; Yoshimoto T
J Med Invest; 2021; 68(3.4):362-367. PubMed ID: 34759159
[TBL] [Abstract][Full Text] [Related]
20. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]